StockTipsArenaBeta

BUY Shilpa Medicare Limited — Kush Bohra

BUYShilpa Medicare Limited
Shilpa Medicare share price target & all analyst calls

byKush BohraHorizon: NA (inferred Swing (≤2wk))8 Nov 2026via NDTV Profit

Entry₹953.65Inferred
Target₹1,100
Total upside +15.35%
Stop loss₹800-16.11% risk
CMP₹991.51d ago
Active+3.97%+10.94%upside left 8d left
Follow Kush Bohra for new calls(35% target hit, 229 closed calls)Get alertsWatch SHILPAMED for new buy/sell callsGet alertsSee 1 other Swing call on SHILPAMEDSee 282 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:32 am IST
9 supporting1 neutral1 opposing
Supports the BUY call (9)

MACD above its signal line — bullish momentum

Technicals · macd·14 Nov · today

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·12 Nov · 2d ago

Shilpa Medicare Limited Posts ₹538 Crore Q2 Revenue, ₹79 Crore PAT

NewsGoogle News·11 Nov · 3d ago

(opens in new tab)

Shilpa Medicare reports highest ever revenue and EBITDA in Q2 FY27

NewsGoogle News·11 Nov · 3d ago

(opens in new tab)

Shilpa Medicare Limited Just Recorded A 12% Revenue Beat: Here's What Analysts Think

NewsGoogle News·8 Nov · 6d ago

(opens in new tab)
Neutral / worth noting (1)

Shilpa Medicare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·5 Nov · 1w ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 71 — overbought territory

Technicals · rsi·14 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Shilpa Medicare

All analyst calls on Shilpa Medicare

More from Kush Bohra

Every call and its outcome